Literature DB >> 16826366

Recruited leukocytes and local synthesis account for increased matrix metalloproteinase-9 activity in cerebrospinal fluid of dogs with central nervous system neoplasm.

Maria Elena Turba1, Monica Forni, Gualtiero Gandini, Fabio Gentilini.   

Abstract

Matrix metalloproteinases (MMP) 2 and 9 are enzymes known to degrade several protein components of the extracellular matrix. In humans, increased concentrations of these enzymes have been demonstrated in the cerebrospinal fluid (CSF) of subjects affected by many neurological conditions including brain tumours; nevertheless comparative data in dogs are completely lacking. Aim of this study was to investigate these molecules in CSF of dogs diagnosed with CNS neurological diseases. Higher activity of MMP 2 and 9 was revealed in dogs with space occupying lesions of likely neoplastic origin in comparison to dogs with idiopathic epilepsy. Statistical modelling reveals that increased MMP 9 activity is mainly due to leukocytes recruitment and local synthesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16826366     DOI: 10.1007/s11060-006-9213-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  22 in total

Review 1.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.

Authors:  H Reiber; J B Peter
Journal:  J Neurol Sci       Date:  2001-03-01       Impact factor: 3.181

Review 2.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.

Authors:  Robert Visse; Hideaki Nagase
Journal:  Circ Res       Date:  2003-05-02       Impact factor: 17.367

Review 3.  Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

Authors:  Christopher M Overall; Oded Kleifeld
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

4.  Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis.

Authors:  M H Friedberg; M J Glantz; M S Klempner; B F Cole; G Perides
Journal:  Cancer       Date:  1998-03-01       Impact factor: 6.860

Review 5.  Angiogenesis in neuroblastoma.

Authors:  Domenico Ribatti; Danilo Marimpietri; Fabio Pastorino; Chiara Brignole; Beatrice Nico; Angelo Vacca; Mirco Ponzoni
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

6.  Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc.

Authors:  S Roberts; B Caterson; J Menage; E H Evans; D C Jaffray; S M Eisenstein
Journal:  Spine (Phila Pa 1976)       Date:  2000-12-01       Impact factor: 3.468

7.  Matrix metalloproteinase-9 activity in the cerebrospinal fluid and serum of dogs with acute spinal cord trauma from intervertebral disk disease.

Authors:  Jonathan M Levine; Craig G Ruaux; Robert L Bergman; Joan R Coates; Jörg M Steiner; David A Williams
Journal:  Am J Vet Res       Date:  2006-02       Impact factor: 1.156

8.  Persistent increase of matrix metalloproteinases in cerebrospinal fluid of tuberculous meningitis.

Authors:  Kyung Yul Lee; Eun Hee Kim; Won Seok Yang; Hyunjeong Ryu; Sang-Nae Cho; Byung In Lee; Ji Hoe Heo
Journal:  J Neurol Sci       Date:  2004-05-15       Impact factor: 3.181

Review 9.  Proteases in brain tumour progression.

Authors:  N Levicar; R K Nuttall; T T Lah; R K Nutall
Journal:  Acta Neurochir (Wien)       Date:  2003-09       Impact factor: 2.216

10.  Matrix metalloproteinase-2 and -9 involvement in canine tumors.

Authors:  P Loukopoulos; B A Mungall; R C Straw; J R Thornton; W F Robinson
Journal:  Vet Pathol       Date:  2003-07       Impact factor: 2.221

View more
  4 in total

Review 1.  Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.

Authors:  Ralf G Rempe; Anika M S Hartz; Björn Bauer
Journal:  J Cereb Blood Flow Metab       Date:  2016-06-20       Impact factor: 6.200

Review 2.  Advances in diagnostic and treatment modalities for intracranial tumors.

Authors:  P J Dickinson
Journal:  J Vet Intern Med       Date:  2014-05-09       Impact factor: 3.333

Review 3.  Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke.

Authors:  Renée J Turner; Frank R Sharp
Journal:  Front Cell Neurosci       Date:  2016-03-04       Impact factor: 5.505

Review 4.  Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors.

Authors:  Andrew D Miller; C Ryan Miller; John H Rossmeisl
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.